Core Insights - STRATA Skin Sciences, Inc. (SSKN) has highlighted findings from a meta-analysis that supports the clinical efficacy of its 308 nm excimer laser technology for treating plaque psoriasis [1][12] - The meta-analysis, published in a peer-reviewed journal, indicates significant improvements in disease severity scores following targeted treatment protocols [1][10] Company Performance - Following the announcement of the meta-analysis, SSKN shares fell more than 8%, and the stock has decreased by 82.3% over the last six months, compared to a 37% decline in the industry [3][8] - The current market capitalization of SSKN is $2 million [6] Clinical Validation and Market Position - The findings from the meta-analysis provide independent validation of SSKN's excimer laser technology, which may enhance physician adoption and patient confidence [4][12] - The pooled data from the analysis showed PASI reductions of 56%-85% within 10-14 treatments, confirming the effectiveness of MED-guided dosing strategies [8][10] - The publication emphasizes the importance of MED-guided calibration for targeted UVB delivery, which can improve treatment outcomes while minimizing damage to healthy skin [11][12] Industry Outlook - The global psoriasis treatment market was valued at $34.14 billion in 2025 and is projected to grow to approximately $73.04 billion by 2035, with a CAGR of 7.9% [13] - The growth in the market is driven by increasing prevalence, better diagnosis, and demand for effective therapies, alongside innovations in biologics and device-based treatments [14]